PPARG and ischemia: For example, rosuvastatin promotes the viability of cardiomyocytes, inhibits the release of LDH, and reduces the production of ROS and the levels of Caspase-9 and cytochrome C to protect primary cardiomyocytes against ischemia-reperfusion injury by upregulating PPARγ and uncoupling protein 2 (UCP2) 43.